Related Experiment Video
Updated: May 5, 2026

06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.3K
The use of mechanical circulatory support in elective high-risk percutaneous coronary interventions: a
Alexander Geppert1, Kambis Mashayekhi2,3, Kurt Huber1,4
13rd Department of Medicine, Cardiology and Intensive Care Medicine, Clinic Ottakring, Montleartstrasse 37, A-1160 Vienna, Austria.
European Heart Journal Open
|March 21, 2024
Summary
Mechanical circulatory support (MCS) devices may aid high-risk percutaneous coronary interventions (HR-PCIs). While IABP use declined, V-A ECMO and Impella show potential, necessitating further trials and a new algorithm for patient selection.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Percutaneous coronary intervention (PCI) is increasingly performed in high-risk patients.
- Mechanical circulatory support (MCS) devices are used to mitigate risks during high-risk PCI (HR-PCI).
- Common MCS devices include intra-aortic balloon pump (IABP), veno-arterial extracorporeal membrane oxygenation (V-A ECMO), and Impella.
Purpose of the Study:
- To review clinical evidence for MCS devices in HR-PCI.
- To explore mechanisms of improved outcomes with MCS in HR-PCI.
- To propose a novel algorithm for identifying suitable candidates for MCS-assisted HR-PCI.
Main Methods:
- Review of contemporary medical literature on MCS devices in HR-PCI.
- Analysis of clinical outcomes associated with IABP, V-A ECMO, and Impella.
- Development of a predictive algorithm for MCS utilization in HR-PCI.
Main Results:
- IABP use has decreased due to lack of demonstrated benefit in HR-PCI and cardiogenic shock.
- V-A ECMO shows low major adverse cardiac and cerebrovascular events (MACCEs) but increased risks of acute kidney injury and transfusion.
- Impella use has seen declining MACCE rates with improved operator experience, though mortality benefits require further investigation via randomized trials.
Conclusions:
- Current evidence for IABP in HR-PCI is limited.
- V-A ECMO and Impella present distinct risk-benefit profiles in HR-PCI.
- A new algorithm combining anatomical, comorbidity, and clinical factors is proposed to optimize MCS selection for HR-PCI.

